Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927666 | 1.00 | HSD11B1 (0.36) | HSD11B1TSHRHSD17B10GRM6ADAM17 | |
| SCHEMBL1841591 | 0.74 | LMNA (0.46) | HSD11B1ADAM17MEN1KMT2AMAOA | |
| SCHEMBL9314420 | 0.74 | HSD11B1 (0.41) | HSD11B1ADAM17MEN1KMT2AMAOA | |
| SCHEMBL16167219 | 0.71 | AKR1C3 (0.38) | HSD11B1MEN1KMT2APOLBGAA | |
| SCHEMBL4580682 | 0.71 | LTB4R (0.36) | HSD11B1 | |
| SCHEMBL17512535 | 0.69 | DPP4 (0.40) | HSD11B1ADAM17MEN1KMT2AMAOA | |
| SCHEMBL17512709 | 0.69 | DPP4 (0.40) | HSD11B1ADAM17MEN1KMT2AMAOA | |
| SCHEMBL6060766 | 0.69 | HPGD (0.38) | HSD11B1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL28556134 | 0.68 | TACR3 (0.41) | HSD11B1MEN1KMT2AMAOAMAOB | |
| SCHEMBL10599609 | 0.68 | ADAM17 (0.41) | HSD11B1HSD17B10GRM6ADAM17GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | HSD11B1 219/4885TSHR 1944/4885HSD17B10 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.